从“罕见”到“被看见” 我国罕见病平均确诊时间从4年降至4周左右

Core Insights - The article highlights significant advancements in the diagnosis and treatment of rare diseases in China, emphasizing the establishment of a collaborative network that enhances accessibility and reduces costs for patients [1][4][6]. Group 1: Diagnosis and Treatment Improvements - As of now, China's rare disease diagnosis and treatment collaboration network covers 419 hospitals, expanding the list of rare diseases and medications covered by insurance [1][4]. - The average diagnosis time for rare disease patients has decreased from over 4 years to approximately 4 weeks, with annual treatment costs reduced by about 90% [4]. - The establishment of a multidisciplinary "one-stop" diagnosis model is breaking the previous barriers faced by rare disease patients who had to navigate multiple departments [4]. Group 2: Clinical Research and AI Integration - Clinical guidelines for 86 rare diseases have been developed, providing comprehensive diagnostic and treatment protocols [7]. - The application of artificial intelligence in clinical settings has led to significant breakthroughs, with over 9,000 effective consultations conducted using the AI model "Xiehe·Taichu" in the past year [7]. - Genetic research related to rare diseases is accelerating, with a focus on understanding the mechanisms behind these conditions, as approximately 80% of rare diseases are linked to genetic factors [7]. Group 3: Policy and Regulatory Support - The Chinese government has included rare disease prevention and treatment in the "Healthy China 2030" plan, indicating a commitment to addressing these health challenges [6]. - Two batches of rare disease directories have been published, listing a total of 207 rare diseases, and a "green channel" for drug approval has been established to expedite the availability of new treatments [8]. - The dynamic adjustment mechanism for insurance coverage is favoring rare disease medications, with over 100 rare disease drugs now included in the insurance guarantee scope [8].